According to a recent LinkedIn post from Cleerly, new data from the INVICTUS registry suggest a 94.4% agreement between the company’s AI-based quantitative coronary CT (AI-QCT) technology and intravascular ultrasound (IVUS), an invasive gold-standard method for coronary plaque quantification. The post attributes the milestone to efforts to make plaque characterization more accurate, accessible, and less invasive across 17 participating centers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that Cleerly is positioning its AI-QCT platform as a clinically competitive alternative to invasive imaging, which could support broader adoption of its technology in cardiology workflows. For investors, this level of concordance with IVUS may strengthen Cleerly’s clinical value proposition, potentially aiding reimbursement discussions, partnership opportunities with providers, and longer-term revenue prospects in the cardiac imaging and preventive cardiology markets.